Vertex’s Bet on T1D, AZ’s Win in T2D CV Outcomes, & FDA Commish Speculation

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.